{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:40:43Z","timestamp":1793227243015,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It has recently become apparent that neuroinflammation may play a significant role in Parkinson's disease (PD). This is also the case in animal paradigms of the disease. The potential neuroprotective action of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 (EX-4), which is protective against cytokine mediated apoptosis and may stimulate neurogenesis, was investigated In paradigms of PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Two rodent 'models' of PD, 6-hydroxydopamine (6-OHDA) and lipopolysaccaride (LPS), were used to test the effects of EX-4. Rats were then investigated\n                      <jats:italic>in vivo<\/jats:italic>\n                      and\n                      <jats:italic>ex vivo<\/jats:italic>\n                      with a wide range of behavioural, neurochemical and histological tests to measure integrity of the nigrostriatal system.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>EX-4 (0.1 and 0.5 \u03bcg\/kg) was given seven days after intracerebral toxin injection. Seven days later circling behaviour was measured following apomorphine challenge. Circling was significantly lower in rats given EX-4 at both doses compared to animals given 6-OHDA\/LPS and vehicle. Consistent with these observations, striatal tissue DA concentrations were markedly higher in 6-OHDA\/LPS + EX-4 treated rats versus 6-OHDA\/LPS + vehicle groups, whilst assay of L-DOPA production by tyrosine hydroxylase was greatly reduced in the striata of 6-OHDA\/LPS + vehicle rats, but this was not the case in rats co-administered EX-4. Furthermore nigral TH staining recorded in 6-OHDA\/LPS + vehicle treated animals was markedly lower than in sham-operated or EX-4 treated rats. Finally, EX-4 clearly reversed the loss of extracellular DA in the striata of toxin lesioned freely moving rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The apparent ability of EX-4 to arrest progression of, or even reverse nigral lesions once established, suggests that pharmacological manipulation of the GLP-1 receptor system could have substantial therapeutic utility in PD. Critically, in contrast to other peptide agents that have been demonstrated to possess neuroprotective properties in pre-clinical models of PD, EX-4 is in current clinical use in the management of type-II diabetes and freely crosses the blood brain barrier; hence, assessment of the clinical efficacy of EX-4 in patients with PD could be pursued without delay.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1742-2094-5-19","type":"journal-article","created":{"date-parts":[[2008,5,21]],"date-time":"2008-05-21T12:50:06Z","timestamp":1211374206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":251,"title":["Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease"],"prefix":"10.1186","volume":"5","author":[{"given":"Alexander","family":"Harkavyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Abuirmeileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E","family":"Kingsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S","family":"Biggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S","family":"Whitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,21]]},"reference":[{"key":"136_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/syn.890010408","volume":"1","author":"D Clark","year":"1987","unstructured":"Clark D, White FJ: Review: D1 dopamine receptor B the search for a function: a critical evaluation of the D1\/D2 dopamine receptor classification and its functional implications. Synapse. 1987, 1: 347-388. 10.1002\/syn.890010408.","journal-title":"Synapse"},{"key":"136_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0092-8674(00)80564-4","volume":"96","author":"DL Vaux","year":"1999","unstructured":"Vaux DL, Korsmeyer SJ: Cell death in development. Cell. 1999, 96: 245-254. 10.1016\/S0092-8674(00)80564-4.","journal-title":"Cell"},{"key":"136_CR3","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1093\/hmg\/ddi308","volume":"14","author":"S Gandhi","year":"2005","unstructured":"Gandhi S, Wood NW: Molecular pathogenesis of Parkinson's disease. Hum Mol Genet. 2005, 14: 2749-2755. 10.1093\/hmg\/ddi308.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"136_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrn2038","volume":"8","author":"ML Block","year":"2007","unstructured":"Block ML, Zecca L, Hong J-S: Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nature Neurosci. 2007, 8 (1): 57-69. 10.1038\/nrn2038.","journal-title":"Nature Neurosci"},{"key":"136_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bjp.0707167","volume":"150","author":"PS Whitton","year":"2007","unstructured":"Whitton PS: Inflammation as a potential causative factor in the aetiology of Parkinsons disease. Br J Pharmacol. 2007, 150: 963-976. 10.1038\/sj.bjp.0707167.","journal-title":"Br J Pharmacol"},{"key":"136_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1006\/exnr.1996.6380","volume":"144","author":"HI Hurtig","year":"1997","unstructured":"Hurtig HI: Problems with current pharmacological treatment of Parkinson's disease. Exp Neurol. 1997, 144: 10-16. 10.1006\/exnr.1996.6380.","journal-title":"Exp Neurol"},{"key":"136_CR7","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1002\/ana.410440721","volume":"44","author":"NA Tatton","year":"1998","unstructured":"Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW: A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol. 1998, 44: S142-148.","journal-title":"Ann Neurol"},{"key":"136_CR8","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1046\/j.1471-4159.1998.70062637.x","volume":"70","author":"EE Ochu","year":"1998","unstructured":"Ochu EE, Rothwell NJ, Waters CM: Caspases mediate 6-hydroxydopamine induced apoptosis but not necrosis in PC12 cells. J Neurochem. 1998, 70: 2637-2640.","journal-title":"J Neurochem"},{"key":"136_CR9","first-page":"155","volume":"86","author":"AH Schapira","year":"2001","unstructured":"Schapira AH: Causes of neuronal death in Parkinson's disease. Adv Neurol. 2001, 86: 155-162.","journal-title":"Adv Neurol"},{"key":"136_CR10","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1124\/jpet.300.3.958","volume":"300","author":"T Perry","year":"2002","unstructured":"Perry T, Lahiri DK, Chen D, Zhou J, Shaw KTY, Egan JM, Grieg NH: A novel neurotrophic property of glucagons-like peptide 1: a promoter of nerve cell growth factor mediated differenciation in PC12 cells. J Pharmacol Exp Ther. 2002, 300: 958-966. 10.1124\/jpet.300.3.958.","journal-title":"J Pharmacol Exp Ther"},{"key":"136_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1124\/jpet.102.037481","volume":"302","author":"TA Perry","year":"2002","unstructured":"Perry TA, Haughey NJ, Mattson MP, Egan JM, Grieg NH: Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002, 302: 881-888. 10.1124\/jpet.102.037481.","journal-title":"J Pharmacol Exp Ther"},{"key":"136_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.expneurol.2006.09.028","volume":"203","author":"TA Perry","year":"2007","unstructured":"Perry TA, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Grieg NH: Evidence of GLp-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 2007, 203: 293-301. 10.1016\/j.expneurol.2006.09.028.","journal-title":"Exp Neurol"},{"key":"136_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1074\/jbc.M209423200","volume":"278","author":"L Li","year":"2003","unstructured":"Li L, El-Kholy W, Rhodes CJ, Brubaker PL: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003, 278: 471-478. 10.1074\/jbc.M209423200.","journal-title":"J Biol Chem"},{"key":"136_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jnr.21483","volume":"86","author":"G Bertilsson","year":"2008","unstructured":"Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannnaeus K, Heidrich J, Kortesmaa J, Mercer A, Neilsen E, Ronnholm H, Wilkstrom L: Peptide hormone exndin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease. J Neurosci Res. 2008, 86: 326-38. 10.1002\/jnr.21483.","journal-title":"J Neurosci Res"},{"key":"136_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/1096-9861(20001120)427:3<440::AID-CNE10>3.0.CO;2-7","volume":"427","author":"CL Zuch","year":"2000","unstructured":"Zuch CL, Nordstroem VK, Briedrick LA, Hoernig GR, Granholm AC, Bickford PC: Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J Comp Neurol. 2000, 427: 440-454. 10.1002\/1096-9861(20001120)427:3<440::AID-CNE10>3.0.CO;2-7.","journal-title":"J Comp Neurol"},{"key":"136_CR16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3727\/000000007783464632","volume":"16","author":"T Yasuhara","year":"2007","unstructured":"Yasuhara T, Shingo T, Date I: Intracerebral transplantation of genetically engineered cells for Parkinson's disease: toward clinical application. Cell Transplant. 2007, 16: 125-132.","journal-title":"Cell Transplant"},{"key":"136_CR17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1136\/gut.2005.084525","volume":"55","author":"E Gonzalez-Rey","year":"2006","unstructured":"Gonzalez-Rey E, Fernandez-Martin A, Chomy A, Delgado M: Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut. 2006, 55: 824-32. 10.1136\/gut.2005.084525.","journal-title":"Gut"},{"key":"136_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1460-9568.2007.05653.x","volume":"26","author":"A Abuirmeileh","year":"2007","unstructured":"Abuirmeileh A, Lever R, Kingsbury AE, Lees AJ, Locke IC, Knight RA, Chowdrey HS, Biggs CS, Whitton PS: The corticotrophin releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson = s disease. Eur J Neurosci. 2007, 26: 417-423. 10.1111\/j.1460-9568.2007.05653.x.","journal-title":"Eur J Neurosci"},{"key":"136_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-2094-4-19","volume":"4","author":"A Abuirmeileh","year":"2007","unstructured":"Abuirmeileh A, Harkavyi A, Lever R, Biggs CS, Whitton PS: Urocortin, a CRF-like peptide, restores key indicators of damage in a neuroinflammatory model of Parkinson's disease. J Neuroinflammation. 2007, 4: 19-10.1186\/1742-2094-4-19.","journal-title":"J Neuroinflammation"},{"key":"136_CR20","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.2337\/dc06-0864","volume":"29","author":"AB King","year":"2006","unstructured":"King AB, Wolfe G, Healy S: Clinical observations of exenatide treatment. Diabetes Care. 2006, 29: 1984-10.2337\/dc06-0864.","journal-title":"Diabetes Care"},{"key":"136_CR21","first-page":"8993","volume":"367","author":"U Ungerstedt","year":"1971","unstructured":"Ungerstedt U: Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971, 367: 8993.","journal-title":"Acta Physiol Scand Suppl"},{"key":"136_CR22","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1111\/j.1471-4159.1992.tb11001.x","volume":"59","author":"CS Biggs","year":"1992","unstructured":"Biggs CS, Fowler LJ, Pearce BR, Whitton PS: Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine and their metabolites in the rat brain: An in vivo microdialysis study. J Neurochem. 1992, 59: 1702-1708. 10.1111\/j.1471-4159.1992.tb11001.x.","journal-title":"J Neurochem"},{"key":"136_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0378-4347(88)80125-7","volume":"427","author":"M Naoi","year":"1988","unstructured":"Naoi M, Takahashi T, Nagatsu T: Simple assay procedure for tyrosine hydroxylase activity by high-performance liquid chromatography employing coulometric detection with minimal sample preparation. J Chromatogr. 1988, 427: 229-38. 10.1016\/0378-4347(88)80125-7.","journal-title":"J Chromatogr"},{"key":"136_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/0006-8993(90)91318-B","volume":"525","author":"ED Abercrombie","year":"1990","unstructured":"Abercrombie ED, Bonatz AE, Zigmond MJ: Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 1990, 525: 36-44. 10.1016\/0006-8993(90)91318-B.","journal-title":"Brain Res"},{"key":"136_CR25","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1097\/00001756-199908200-00030","volume":"10","author":"B Cutillas","year":"1999","unstructured":"Cutillas B, Espejo M, Gil J, Ferrer I, Ambrosio S: Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration. Neuroreport. 1999, 10: 2605-2608. 10.1097\/00001756-199908200-00030.","journal-title":"Neuroreport"},{"key":"136_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1006\/nbdi.2000.0289","volume":"7","author":"AJ Herrera","year":"2000","unstructured":"Herrera AJ, Castano A, Venero JL, Cano J, Machado A: The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on the dopaminergic system. Neurobiol Dis. 2000, 7: 429-447. 10.1006\/nbdi.2000.0289.","journal-title":"Neurobiol Dis"},{"key":"136_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1471-4159.2006.04241.x","volume":"100","author":"A Borta","year":"2007","unstructured":"Borta A, Hoglinger GU: Dopamine and adult neurogenesis. J Neurochem. 2007, 100: 587-595. 10.1111\/j.1471-4159.2006.04241.x.","journal-title":"J Neurochem"},{"key":"136_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.tips.2004.03.003","volume":"25","author":"WT Meissner","year":"2004","unstructured":"Meissner WT, Hill MP, Tison F, Gross CE, Bezard E: Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci. 2004, 25: 249-253. 10.1016\/j.tips.2004.03.003.","journal-title":"Trends Pharmacol Sci"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-2094-5-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:03:35Z","timestamp":1630436615000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/1742-2094-5-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,21]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1186\/1742-2094-5-19","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,21]]},"assertion":[{"value":"4 March 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"19"}}